U.S. markets close in 3 hours 4 minutes

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
267.17-2.16 (-0.80%)
As of 12:45PM EST. Market open.

argenx SE

Willemstraat 5
Breda 4811 AH
Netherlands
31 763 030 488
http://www.argenx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees186

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBACEO & Exec. DirectorN/AN/A1972
Mr. Eric CastaldiChief Financial OfficerN/AN/A1964
Mr. R. Keith WoodsChief Operating OfficerN/AN/A1968
Prof. Hans de HaardChief Scientific OfficerN/AN/A1960
Mr. Dirk Marcel Leon Beeusaert L.L.M.Gen. CounselN/AN/A1964
Mr. Arjen Lemmen M.Sc.VP of Corp. Devel. & StrategyN/AN/A1985
Dr. Wim Parys M.D.Chief Medical OfficerN/AN/A1960
Joke ComijnDirector Corp. Communications & Investor Relations (EU)N/AN/AN/A
Mr. Marc SchorpionGlobal Head of HRN/AN/AN/A
Ms. Andria WilkGlobal Head of Quality AssuranceN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Corporate Governance

argenx SE’s ISS Governance QualityScore as of November 1, 2019 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.